antigen

(redirected from carcinoembryonic)
Also found in: Thesaurus, Medical, Encyclopedia.

an·ti·gen

 (ăn′tĭ-jən) also an·ti·gene (-jēn′)
n.
A molecule that is capable of binding to an antibody or to an antigen receptor on a T cell, especially one that induces an immune response. An antigen is usually a foreign substance, such as a toxin or a component of a virus, bacterium, or parasite.

an′ti·gen′ic (-jĕn′ĭk) adj.
an′ti·gen′i·cal·ly adv.
an′ti·ge·nic′i·ty (-jə-nĭs′ĭ-tē) n.

antigen

(ˈæntɪdʒən; -ˌdʒɛn) or

antigene

n
(Biochemistry) a substance that stimulates the production of antibodies
[C20: from anti(body) + -gen]
ˌantiˈgenic adj
ˌantiˈgenically adv

an•ti•gen

(ˈæn tɪ dʒən, -ˌdʒɛn)

n.
1. any substance that can stimulate the production of antibodies and combine specifically with them.
2. any commercial substance that, when injected or absorbed into animal tissues, stimulates the production of antibodies.
3. antigens of a particular type collectively.
[1905–10; anti (body) + -gen]
an`ti•gen′ic, adj.
an`ti•gen′i•cal•ly, adv.
an`ti•ge•nic′i•ty (-dʒəˈnɪs ɪ ti) n.

an·ti·gen

(ăn′tĭ-jən)
A substance that stimulates the production of an antibody when introduced into the body. Antigens include toxins, bacteria, viruses, and other foreign substances. See Note at blood type.

antigen

A molecule recognized as foreign by the body’s immune system, causing the release of antibodies.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.antigen - any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)
substance - a particular kind or species of matter with uniform properties; "shigella is one of the most toxic substances known to man"
immunizing agent, immunogen - any substance or organism that provokes an immune response (produces immunity) when introduced into the body
immunology - the branch of medical science that studies the body's immune system
agglutinogen - any substance that acts as an antigen to cause agglutinin production
fetoprotein, foetoprotein - any of several antigens that occur naturally in the fetus and sometimes in adults with cancer
anatoxin, toxoid - a bacterial toxin that has been weakened until it is no longer toxic but is strong enough to induce the formation of antibodies and immunity to the specific disease caused by the toxin; "diphtheria toxoid"
antigenic determinant, epitope, determinant - the site on the surface of an antigen molecule to which an antibody attaches itself
Rh, Rh factor, rhesus factor - a blood group antigen possessed by Rh-positive people; if an Rh-negative person receives a blood transfusion from an Rh-positive person it can result in hemolysis and anemia
Translations
antigen
antigeeni
antigén
antígeno
antigen
antigen

antigen

[ˈæntɪdʒən] Nantígeno m

antigen

[ˈæntɪdʒən] nantigène manti-hero antihero [ˈæntihɪərəʊ] nantihéros m

antigen

nAntigen nt

antigen

[ˈæntɪdʒən] nantigene m

an·ti·gen

n. antígeno, sustancia tóxica que estimula la formación de anticuerpos;
carcinoembriogenic ______ carcinoembriogénico.

antigen

n antígeno; carcinoembryonic — antígeno carcinoembrionario; prostate-specific — (PSA) antígeno prostático específico (APE)
References in periodicals archive ?
The serum level of tumor marker including carcinoembryonic antigen and carbohydrate antigen 19-9 were 3.08 ng/mL and 0.6 U/mL, respectively.
In addition, staining for carcinoembryonic antigen was made and it was positive (Figure 3 B).
Global carcinoembryonic antigen market segmented based on application of carcinoembryonic antigen: malignant condition and non-malignant condition.
Summary: Global carcinoembryonic antigen market segmented based on application of carcinoembryonic antigen: malignant condition and non-malignant condition.
FameWave, which is being acquired by Kitov Pharmaceuticals (KTOV), announced the signing of a clinical collaboration with Bristol Myers (BMY) to evaluate the combination of CM-24, FameWave's monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related cell adhesion molecule 1, or CEACAM1, with nivolumab, a PD-1 inhibitor, in patients with non-small cell lung cancer, or NSCLC.
Serum tumour marker carcinoembryonic antigen (CEA) also plays an important role in diagnosis and prognosis of lung cancer.
Clinical data of all patients, including age, gender, clinical presentation, clinical and pathological tumour-nodes-metastasis classification, neoadjuvant chemo-radiotherapy, surgery, adjuvant chemotherapy, pre-and postoperative carcinoembryonic antigen levels, histopathological findings and tumour recurrence were analysed.
Immunohistochemical is favorable for antidiastole, especially prostate-specific antigen (PSA), carcinoembryonic antigen, and carcinoembryonic antigen 125.
Preoperative serum tumor markers, including carcinoembryonic antigen, CA 125, CA 19-9, and, in one case, squamous cell carcinoma antigen, have been within normal limits.
The authors based the model on a panel of selected circulating protein biomarkers (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]) and compared its performance to a traditional risk prediction model and current U.S.
Serum carcinoembryonic antigen (CEA) is a glycolyzed antigen, which is secreted into the lumen after expression on the apical surface of colonic epithelial cells [3].
In contrast, carcinoembryonic antigen has been used as a biomarker of prognosis and therapeutic efficacy in non-small cell lung cancer.